Web21 feb. 2024 · As a part of this agreement, Hutchmed will receive $400 million as upfront payment and up to $1.13 billion on closing of this agreement including "potential regulatory, development and commercial sales milestone payments, plus royalties on net sales." Shares of Hutchmed soared by more than 8% following this announcement. WebHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer …
HUTCHMED (China) Ltd (ADR) (HCM) AAII Stock Evaluator
Web13 apr. 2024 · 美國預託證券ADR. ... 個股新聞 - HUTCHMED (China) Limited. 回上頁 《大行報告》摩通:近期樓市交投疲弱 提供吸納新地(00016.HK)機會 ... Web11 apr. 2024 · HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. jeremy jojola instagram
HCM - Hutchmed China Ltd ADR Stock Price - Barchart.com
Web24 mrt. 2024 · Company profile for HUTCHMED (China) Ltd. ADR including key executives, insider trading, ownership, revenue and average growth rates. View detailed HCM … WebHUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for … Web28 mrt. 2024 · 52-wk low: $7.39. Bid: $12.65. Ask: $14.20. Company Information. HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. jeremy jezza